“Investerarafton” was recorded on 5 November 2019 in Stockholm, Sweden.
Founded in 2004 in Denmark and publicly traded on NASDAQ First North (Stockholm).
Robust Pipeline of 7 novel anti-cancer drugs that address significant cancer markets.
Best-in-class DRP® platform creates drug-specific, predictive diagnostics to:
Strong intellectual property position with over 30 patents/applications in key world markets, covering DRP® diagnostics for more than 75 different cancer drugs.
By combining cutting-edge science from the fields of genetics and oncology, Oncology Venture is the first to develop a Drug Response Predictor®, which can be combined with ultimately any cancer drug. Using this technology, our offset is treating the particular genetic characteristics of the tumor instead of the type of cancer, which has been the traditional treatment approach. Because cancers are different. Just like people.
Receive our investor newsletter with relevant information about Oncology Venture
Venlighedsvej 1
DK-2970 Hørsholm
Denmark
CVR: 2810 6351
Tel. +45 53 61 15 70
9977 N 90th Street, Suite 175
Scottsdale, Arizona 85258
USA